These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1416 related items for PubMed ID: 17627161

  • 1. Hormonal predictors of prostate cancer.
    Sofikerim M, Eskicorapci S, Oruç O, Ozen H.
    Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
    [Abstract] [Full Text] [Related]

  • 2. High-grade prostate cancer is associated with low serum testosterone levels.
    Schatzl G, Madersbacher S, Thurridl T, Waldmüller J, Kramer G, Haitel A, Marberger M.
    Prostate; 2001 Apr; 47(1):52-8. PubMed ID: 11304729
    [Abstract] [Full Text] [Related]

  • 3. [Serum testosterone, dihydrotestosterone, luteinizing hormone and follicle-stimulating hormone versus prostate specific antigen in patients with localized prostate adenocarcinoma who underwent radical prostatectomy. Radioimmunoassays measurements].
    Bantis A, Zissimopoulos A, Athanasiadou P, Gonidi M, Agelonidou E, Strataki A, Matthaios D, Tsartsarakis A.
    Hell J Nucl Med; 2007 Apr; 10(1):56-61. PubMed ID: 17450256
    [Abstract] [Full Text] [Related]

  • 4. Investigative clinical study on prostate cancer part VI: Follicle-stimulating hormone and the pituitary-testicular-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population.
    Porcaro AB, Migliorini F, Petrozziello A, Sava T, Romano M, Caruso B, Cocco C, Ghimenton C, Zecchinini Antoniolli S, Lacola V, Rubilotta E, Monaco C, Comunale L.
    Urol Int; 2012 Apr; 88(2):150-7. PubMed ID: 22205171
    [Abstract] [Full Text] [Related]

  • 5. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
    Kobayashi T, Nishizawa K, Mitsumori K.
    Scand J Urol Nephrol; 2006 Apr; 40(3):198-203. PubMed ID: 16809259
    [Abstract] [Full Text] [Related]

  • 6. The clinical potential of pretreatment serum testosterone level to improve the efficiency of prostate cancer screening.
    Yano M, Imamoto T, Suzuki H, Fukasawa S, Kojima S, Komiya A, Naya Y, Ichikawa T.
    Eur Urol; 2007 Feb; 51(2):375-80. PubMed ID: 17005316
    [Abstract] [Full Text] [Related]

  • 7. The relationship between total and free serum testosterone and the risk of prostate cancer and tumour aggressiveness.
    Morote J, Ramirez C, Gómez E, Planas J, Raventós CX, de Torres IM, Catalán R.
    BJU Int; 2009 Aug; 104(4):486-9. PubMed ID: 19220251
    [Abstract] [Full Text] [Related]

  • 8. Development of a nomogram for predicting high-grade prostate cancer on biopsy: the significance of serum testosterone levels.
    Ide H, Yasuda M, Nishio K, Saito K, Isotani S, Kamiyama Y, Muto S, Horie S.
    Anticancer Res; 2008 Aug; 28(4C):2487-92. PubMed ID: 18751439
    [Abstract] [Full Text] [Related]

  • 9. Predictive criteria for prostate cancer detection in men with serum PSA concentration of 2.0 to 4.0 ng/mL.
    Kravchick S, Peled R, Dorfman D, Agulansky L, Ben-Dor D, Cytron S.
    Urology; 2005 Sep; 66(3):542-6. PubMed ID: 16140074
    [Abstract] [Full Text] [Related]

  • 10. Early and late long-term effects of vasectomy on serum testosterone, dihydrotestosterone, luteinizing hormone and follicle-stimulating hormone levels.
    Mo ZN, Huang X, Zhang SC, Yang JR.
    J Urol; 1995 Dec; 154(6):2065-9. PubMed ID: 7500459
    [Abstract] [Full Text] [Related]

  • 11. The effect of high grade prostatic intraepithelial neoplasia on serum total and percentage of free prostate specific antigen levels.
    Ramos CG, Carvahal GF, Mager DE, Haberer B, Catalona WJ.
    J Urol; 1999 Nov; 162(5):1587-90. PubMed ID: 10524873
    [Abstract] [Full Text] [Related]

  • 12. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
    Hammarsten J, Högstedt B.
    Scand J Urol Nephrol; 2002 Nov; 36(5):330-8. PubMed ID: 12487736
    [Abstract] [Full Text] [Related]

  • 13. Polymorphism in ARE-I region of prostate-specific antigen gene associated with low serum testosterone level and high-grade prostate cancer.
    Schatzl G, Marberger M, Remzi M, Grösser P, Unterlechner J, Haidinger G, Zidek T, Preyer M, Micksche M, Gsur A.
    Urology; 2005 Jun; 65(6):1141-5. PubMed ID: 15893813
    [Abstract] [Full Text] [Related]

  • 14. [Clinical usefulness of free PSA/total PSA ratio in the early diagnosis of prostatic cancer].
    Laguna Pes MP, Guinda Sevillano C, Zazo Romojaro A, Domínguez J, García Luzón A, Borrego Hernando J, Gimeno Collado A.
    Arch Esp Urol; 2000 May; 53(4):333-41. PubMed ID: 10900763
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of the serum testosterone to prostate-specific antigen ratio as a predictor of prostate cancer risk.
    Morote J, Planas J, Ramirez C, Gómez E, Raventós CX, Placer J, Catalán R, de Torres IM.
    BJU Int; 2010 Feb; 105(4):481-4. PubMed ID: 19681902
    [Abstract] [Full Text] [Related]

  • 16. [Predictive value of prostate specific antigen density in the detection of prostate cancer in patients with elevated prostate specific antigen levels and normal digital rectal findings or stage A prostate cancer].
    Iwaki H, Kajita Y, Shimizu Y, Yamauchi T.
    Hinyokika Kiyo; 2001 Mar; 47(3):169-74. PubMed ID: 11329957
    [Abstract] [Full Text] [Related]

  • 17. Influence of radical prostatectomy on serum hormone levels.
    Miller LR, Partin AW, Chan DW, Bruzek DJ, Dobs AS, Epstein JI, Walsh PC.
    J Urol; 1998 Aug; 160(2):449-53. PubMed ID: 9679896
    [Abstract] [Full Text] [Related]

  • 18. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
    Haese A, Dworschack RT, Partin AW.
    J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
    [Abstract] [Full Text] [Related]

  • 19. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
    Trojan L, Bode C, Weiss C, Mayer D, Grobholz R, Alken P, Michel MS.
    Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
    [Abstract] [Full Text] [Related]

  • 20. Investigative clinical study on prostate cancer part VII: prolactin and the pituitary-testis-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population.
    Porcaro AB, Ghimenton C, Petrozziello A, Migliorini F, Romano M, Sava T, Caruso B, Cocco C, Antoniolli SZ, Lacola V, Rubilotta E, Monaco C, Comunale L.
    Anticancer Res; 2011 Nov; 31(11):3913-20. PubMed ID: 22110219
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 71.